Windlas Biotech

What Windlas Biotech does

Windlas Biotech Limited is an Indian pharmaceutical contract development and manufacturing organization (CDMO) founded in 2001 and headquartered in Dehra Dun, India. The company manufactures pharmaceutical, nutraceutical, and ayurvedic products on a contract basis for third-party clients. It operates as a public limited company listed on India's National Stock Exchange (NSE) with a workforce of 1,001-5,000 employees, and is described in source material as a for-profit enterprise with no identified parent entity.

The company's core business is providing end-to-end contract development and manufacturing services to pharmaceutical and wellness-product companies seeking outsourced production capacity. Its product surface spans three categories — pharmaceutical formulations, nutraceuticals, and ayurvedic products — providing cross-segment exposure across regulated and traditional medicine formats. Underlying capabilities center on pharmaceutical formulation, scale-up, and commercial manufacturing, with distribution conducted exclusively through direct B2B sales to enterprise clients in the domestic Indian market; no international operations, channel partnerships, or app/digital platform presence were disclosed in the available source material.

Windlas generates revenue through a professional services-oriented model, collecting manufacturing and development fees from clients, though specific pricing structures are not publicly disclosed. The company addresses outsourced manufacturing needs for pharmaceutical firms requiring external development and production capability, with a stated horizontal segmentation approach (i.e., serving a broad base of customers across categories rather than concentrating in a single vertical). Its value proposition is functional rather than differentiated: it competes as a domestic multi-category CDMO rather than via proprietary technology, brand differentiation, or specialized regulatory positioning, and the available source material discloses no specific competitive differentiators or quantifiable customer outcomes.

Name

Windlas Biotech

Legal name

Windlas Biotech Limited

Website

https://windlas.com

Company type

Public

Founded year

2001

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Windlas Biotech Limited is an Indian pharmaceutical CDMO founded in 2001 that contract-manufactures pharmaceutical, nutraceutical, and ayurvedic products for B2B clients. Headquartered in Dehra Dun with 1,001-5,000 employees, it is listed on India's NSE and earns revenue via contract manufacturing fees.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

Keywords

• Pharmaceutical contract manufacturing
• CDMO services
• Nutraceutical manufacturing
• Ayurvedic formulations
• Drug development services

Headquarters

HQ city

Dehra Dun

HQ country

India

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Contract Manufacturing Services: Windlas Biotech operates as a pharmaceutical CDMO providing contract development and manufacturing services. Revenue generated through manufacturing fees for pharmaceutical products developed for clients.

Distribution channels1 record

Core offering

Windlas Biotech is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) providing contract development and manufacturing services for pharmaceutical, nutraceutical, and ayurvedic products. The company manufactures products on behalf of third-party clients, generating revenue through manufacturing fees. It operates as an end-to-end outsourced manufacturing partner for pharmaceutical companies.

Product overview

Windlas Biotech is a pharmaceutical contract development and manufacturing organization (CDMO) that develops and manufactures pharmaceutical products for third-party clients. The source material does not provide detailed information about specific product brands, modules, or named offerings beyond this general description.

Differentiator

Problem solved

Functional benefit

Products and services

• Contract Development and Manufacturing Services (CDMO) End-to-end pharmaceutical contract development and manufacturing services for third-party clients, covering formulation development and production of pharmaceutical products. Targeted at pharmaceutical companies seeking outsourced manufacturing capacity.
• Nutraceutical Product Manufacturing Contract manufacturing of nutraceutical products for client companies, providing formulation and production capacity for dietary supplements and nutritional formulations.
• Ayurvedic Product Manufacturing Contract manufacturing of ayurvedic formulations and traditional medicine products for client companies requiring production capacity in the traditional-medicine segment.

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators8 records

Recent moves3 records

Expansion highlights3 records

Broad incumbents

• Lonza Group: Lonza is the world's largest pharmaceutical CDMO offering end-to-end drug substance and drug product manufacturing globally. As a broad incumbent it anchors the global CDMO benchmark for services, scale, and regulatory reach relevant to Windlas's potential global expansion.
• Aurobindo Pharma: Aurobindo Pharma is one of India's largest generic pharmaceutical manufacturers with a sizable contract manufacturing business across formulations and APIs. While much larger than Windlas, it competes for similar pharma CDMO contracts and is a relevant broad industry peer.

Direct peers

• Laurus Labs: Laurus Labs is an Indian-listed pharmaceutical manufacturer and CDMO with strong APIs and formulation capabilities serving global generics and innovator customers. It competes with Windlas for pharma contract manufacturing clients, particularly in APIs and oral solids.
• Syngene International: Syngene International is India's largest listed CRO/CDMO offering integrated drug discovery, development, and manufacturing services to global pharma clients. It is the most directly comparable Indian-listed peer to Windlas Biotech given its pharmaceutical contract development and manufacturing mandate at similar scale.
• Hikal: Hikal is an Indian-listed fine chemicals and pharmaceutical CDMO manufacturer of APIs and intermediates serving pharma and agro customers. It is comparable to Windlas as a domestic CDMO with overlapping contract manufacturing capabilities.
• Neuland Laboratories: Neuland Laboratories is an India-listed pharmaceutical CDMO offering contract development and manufacturing of APIs and intermediates, including peptides. Comparable to Windlas as a focused pharma CDMO serving global innovator customers from India.
• Suven Pharmaceuticals: Suven Pharmaceuticals is an India-listed CDMO providing contract development and manufacturing services for APIs and intermediates to global pharma clients. Like Windlas, it is a focused Indian CDMO with comparable scale and target customers.
• Piramal Pharma Solutions: Piramal Pharma Solutions is the CDMO arm of Piramal Pharma offering end-to-end contract development and manufacturing across drug substance and drug product. It is highly comparable to Windlas in scope (full-service pharma CDMO) though larger and backed by the diversified Piramal group.
• Divis Laboratories: Divis Laboratories is a leading Indian API and intermediates manufacturer with significant CDMO/contract research exposure to global innovator pharma. Comparable to Windlas as an India-based pharma contract manufacturer serving international customers.

Emerging players

• Cohance Lifesciences: Cohance Lifesciences is an India-listed CDMO formed via the merger of the API/CDMO businesses of Laurus Labs and other entities, offering contract development and manufacturing across APIs and formulations. It is comparable in scope to Windlas as a domestic pharmaceutical CDMO.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/Windlas-Biotech-Limited-313985065281735

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Windlas Biotech